8 weeks versus 12 weeks of sofosbuvir–velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet
Authors: Amit Goel, Sumit Rungta, Vinod Kumar, Shalimar, Ajay Kumar, Harshita Katiyar, Surender Singh, Amar Deep, Ajay Kumar Mishra, Ashish Awasthi, Vikasendu Agarwal, Anurag Kumar Tiwari, Dawesh Prakash Yadav, Sunit Kumar Shukla, Ujjwal Sonika, Radha Krishan Dhiman, Bharat Bhushan Rewari, Rakesh Aggarwal
Institutions: Sanjay Gandhi Post Graduate Institute of Medical Sciences, King George's Medical University, Institute of Medical Sciences, Banaras Hindu University, All India Institute of Medical Sciences, Academy of Scientific and Innovative Research, Government of Uttar Pradesh, World Health Organization Regional Office for South-East Asia
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7214988539